3 studies found for: Hematologic Malignancies | IPI-145
|1||Enrolling by invitation||
A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
† Study has passed its completion date and status has not been verified in more than two years.